Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration

Lasers in Surgery and Medicine

Volumn 43, Issue 10, 2011, Pages 939-942

  Nelson, J Stuart ^a   Jia, Wangcun ^a   Phung, Thuy L ^b   Mihm Jr , Martin C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ACNE; APHTHOUS ULCER; ARTHRALGIA; ARTICLE; DIARRHEA; FATIGUE; FEASIBILITY STUDY; FOLLICULITIS; HEADACHE; HUMAN; NEVUS FLAMMEUS; NONHUMAN; PRIORITY JOURNAL; PULSED DYE LASER; REPERFUSION; RISK BENEFIT ANALYSIS; SAFETY; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WOUND HEALING;

ADULT; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; HUMANS; LASERS, DYE; MALE; PORT-WINE STAIN; SIROLIMUS; TREATMENT OUTCOME;

EID: 83755225261     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21141     Document Type: Article

References (24)

1. Mulliken JB, Young AR,. Vascular birthmarks-hemangiomas, and malformations. Philadelphia, PA: W.B. Saunders Co.; 1988.
2. Jacobs AH, Walton RG,. The incidence of birthmarks in the neonate. Pediatrics 1976; 58: 218-222.
3. Pratt AG,. Birthmarks in infants. Arch Dermatol Syphilol 1953; 67: 302-305.
4. Geronemus RG, Ashinoff R,. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17: 76-79.
5. Lever WF, Schaumburg-Lever G,. Histopathology of the skin, 7th edition. Philadelphia, PA: J.B. Lippincott Co; 1990.
6. Renfro L, Geronemus RG,. Anatomical differences in the treatment of port wine stains with the pulsed dye laser. Arch Dermatol 1993; 29: 182-188. (Pubitemid 23063870)
7. Katugampola GA, Lanigan SW,. Five years' experience of treating port wine stains with the flashlamp-pumped pulsed dye laser. Br J Dermatol 1997; 137: 750-754. (Pubitemid 27496192)
8. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC, Nelson JS,. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med 2008; 40: 1-5. (Pubitemid 351214117)
9. Chiang GG, Abraham RT,. Targeting the mTOR signaling network in cancer. Trends Mol F Med 2007; 13 (10): 433-442. (Epub 2007 Oct 1. PMID: 17905659). (Pubitemid 47570021)
10. Saunders RN, Metcalfe MS, Nicholson ML,. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59: 3-16. (Pubitemid 32055209)
11. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Early R, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Sessa WC, Dvorak HF, Benjamin LE,. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170. (Pubitemid 44175906)
12. Guertin DA, Sabatini DM,. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22. (Pubitemid 47001784)
13. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK,. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
14. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT,. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 20: 7004-7014.
15. Law BK,. Rapamycin: An anti-cancer immunosuppressant. Crit Rev Onc/Hematol 2005; 56: 47-60.
16. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M,. Antitumor activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2007; 48: E27-E29.
17. Henry I, Neukirch C, Debray MP, Mignon F, Crestani B,. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Int Med 2007; 18: 76-77. (Pubitemid 46091655)
18. Morton JM, McLean C, Booth SS, Snell GI, Whitford HM,. Regression of pulmonary lymphangioleiomyomatosis (PLAN)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008; 27: 462-465. (Pubitemid 351418242)
19. Bissler JJ, McCormack FX, Young LR, Elwing JM, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN,. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Eng J Med 2008; 358: 140-151.
20. Stallone G, Schena A, Infante B, DiPaolo S, Loverrre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G,. Sirolimus for Kaposi's sarcoma in renal transplant patients. New Eng J Med 2005; 352: 1317-1323. (Pubitemid 40411498)
21. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A,. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152: 758-764. (Pubitemid 40571311)
22. Haemel AK, O'Brian AL, Teng JM,. Topical rapamycin: A novel approach to facial angiofibromas and tuberous sclerosis. Arch Dermatol 2010; 146Z: 715-718.
23. Jia W, Sun V, Tran N, Choi B, Liu SW, Mihm MC, Phung TL, Nelson JS,. Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: Implications for effective port wine stain treatment. Lasers Surg Med 2010; 42: 105-112.
24. Loewe R, Oble DA, Valera T, Zukerberg L, Mihm MC, Nelson JS,. Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration. J Cutan Pathol 2010; 37: 76-82.